1. HYALURONIC ACID (HA), CRYOGEL, ZERONA WITH
ENDYMED’S PURE 3DEEP TECHNOLOGY COMBINATION
PROTOCOL!
Written By:
Noelle Tenaglia
Lou Tenaglia
November 20, 2014
I (Noelle Tenaglia) have found by incorporating the usage of Hyaluronic Acid (HA)
and Cryogel, Zerona with EndyMed’s Pure 3Deep technology helps to increase the
effectiveness of this Radio Frequency (RF) ability. By “heating” the area(s) with
Zerona and EndyMed along with the application of the HA/Cryogel accelerates the
ability to of the above listed technologies to provide more effective results.
Research shows Hyaluronic Acid (abbreviated to as HA) and Cryogel cross-linked to
be a very effective combination. I have found this effective combination to have
multiple applications
There is a provided process for preparing a HA cryogel, the process comprising the
steps of combining HA, a cross-linking agent and a solvent to form a solution,
freezing the solution before the formation of less than 10% of the cross-linking
bonds of the cross-linked HA cryogel formed and thawing the solution.
Cryogels are a new class of materials with a highly porous structure and having a
broad variety of morphologies. Cryogels are produced using a cryotropic gelation
technique. Cryotropic gelation (cryogelation or cryostructuration) is a specific type
of gel- formation which takes place as a result of cryogenic treatment of the systems
potentially capable of gelation. One particular study shows the use of the cryogel as
claimed in any one of claims 21 to 26 participants effective for use in the
manufacture of a medicament for tissue augmentation, cosmetic surgery, wound
dressing, post surgical adhesion prevention, regenerative medicine applications,
and tissue engineering applications or for use as a scaffold for the incorporation of
cells for tissue repair.
1

2. Hyaluronic acid (also known as hyaluronan or sodium hyaluronate, and abbreviated
to as HA) is a non-sulfated glycosaminoglycan which is distributed widely
throughout connective, epithelial, and neural tissues. It is one of the main
components of the extracellular matrix, contributes significantly to cell proliferation
and migration, and may also be involved in the progression of some malignant
tumors.
For example, HA is a major component of the synovial fluid and has been found to
increase the viscosity of the fluid. Along with lubricant, it is one of the fluid's main
lubricating components. HA is an important component of articular cartilage, where
it is present as a coat around each cell (chondrocyte). When aggrecan monomers
bind to HA in the presence of link protein, large highly negatively charged
aggregates form. These aggregates imbibe water and are responsible for the
resilience of cartilage (its resistance to compression). The molecular weight (size) of
HA in cartilage decreases with age, but the amount increases. HA is also a major
component of skin, where it is involved in tissue repair. When skin is excessively
exposed to UVB rays, HA acts as a free radical scavenger, absorbing free radicals to
degrade. The skin becomes inflamed (sunburn); the cells in the dermis stop
producing as much HA and increase the rate of its degradation. HA degradation
products also accumulate in the skin after UV exposure.
HA is nontoxic, non-immunogenic and biodegradable. HA is degraded by a family of
enzymes called hyaluronidases. In humans, there are at least seven types of
hyaluronidase-like enzymes, several of which are tumor suppressors. HA
derivatives represent an alternative treatment option for the aging face, particularly
for facial lines, for lip augmentation and for treatment of distensible atrophic facial
scarring.
It is known that HA and the like, degrade at low temperature. In particular, it is
recommended that hyaluronic acid gels are not frozen in order to avoid structural
degradation. As such, there is a prejudice in the art against subjecting HA to low
temperatures. It has been found that using the process described above, hyaluronic
acid (and its derivatives), can be cross-linked at or below the freezing point of
several solvents or solvent systems to provide a cryogel. Surprisingly, contrary to
the prejudice in the art, reducing the temperature of the HA during processing to
form a cryogel does not result in structural degradation leading to high free HA (un-cross-
linked HA).
2

3. To summarize these findings on the HA/Cryogel has been shown in the studies to be
very compatible compounds. However, the cross-linking process of these
compounds; which each have there own amazing functionalities, creates an even
more effective product.
Then I have found by taking this invention of (HA)/Cryogel in the field of biomedical
engineering and applying it with my technique with the EndyMed and Zerona
technology not only helps to penetrate into the layers of the tissue, increases the
ability for skin to tighten, increase skin elasticity, body fat site reduction and fluid
reduction on all areas of the body. Specifically my patient,{(X) for HIPPA purposes
will remain anonymous}, I found when tightening the frontal neck region that the
patient tended to have a lot of fluid build up on upper spinal region. Patient (X)
stated reoccurring tension headaches and Migraines with shoulder pain. With the
combination treatment of HA/Cryogel, EndyMed, and Zerona I found that this
combination was able to reduce the spinal fluid on upper extremities, along with
drainage of fluid on the entire spinal column.
Conclusion
Under the conditions of this study this preliminary result demonstrates the cross-linked
Hyaluronic Acid (HA) under cryo-condition (Cryogel) won't have adverse
effects on cell growth to show the cell biocompatibility yet combined with Zerona
and EndyMed’s Pure 3Deep technology yields sigfinacant results in many areas
outside of yet to be studied capabilities. Hyaluronic Acid (HA) and Cryogel combined
with provided research has proven capabilities. The technique, product
development enhancements, and technology will open a new biomedical along with
non-surgical procedure that our findings show with the clinical data yields greater
effect that either product or technology can do alone.Various modifications and
variations to the described embodiments of the invention will be apparent to those
skilled in the art without departing from the scope and spirit of the invention.
Although the invention has been described in connection with specific preferred
embodiments, it should be understood that the invention as claimed should not be
unduly limited to such specific embodiments. Indeed, various modifications of the
described modes of carrying out the invention which are obvious to those skilled in
the art are intended to be covered by the present invention.
3

4. Patent Citations
Cited Patent Filing date Publication date Applicant Title
1 * Jul 24, 2003 Feb 12, 2004 Jasper Ltd Liability
WO2004013182A
Co
Hyaluronic acid
derivatives
EP1459772A1 * Dec 13, 2002 Sep 22, 2004 Yasuharu Noishiki
Fistula formation-inducing
material
and body insertion
device
EP1552839A1 * Aug 16, 2002 Jul 13, 2005
Denki Kagaku
Kogyo Kabushiki
Kaisha
Separate type
medical material
JP2000248002A * Title not available
US20030087850 * Jul 10, 2001 May 8, 2003 Philip Dehazya Gene therapy for
dry eye syndrome
* Cited by examiner
Referenced by
Citing Patent Filing
date
Publication
date Applicant Title
WO2012112410A
2 *
Feb 13,
2012 Aug 23, 2012 Mimedx
Group Inc.
Micronized placental tissue compositions
and methods for making and using the
same
WO2013021249A
1
Jul 31,
2012 Feb 14, 2013 Glycores
2000 S.R.L.
Degradation-resistant cross-linked, low-molecular-
weight hyaluronate
* Cited by examiner
Nov 19th, 2014 Luciano Tenaglia
4